Evidence-based answers to your most important COVID-19 questions
We are committed to factual accuracy. When we get something wrong, we correct it promptly and transparently.
CoronavirusQuestions.com draws on CDC, WHO, FDA, NIH, and peer-reviewed literature as primary sources. Guidance pages are reviewed monthly against current authority guidance using an automated process that checks for direct factual contradictions. Despite these measures, errors can occur.
When a factual error is identified — whether by a reader, a clinician, or our own review process — we correct it as quickly as possible. We do not silently remove incorrect content; we replace it with the accurate information and note the correction where the change is material.
A correction applies to factual claims that are:
Corrections do not apply to editorial judgments, matters of interpretation where reasonable sources disagree, or content that is a matter of emphasis rather than fact. COVID-19 guidance has evolved significantly since 2020; pages note the date of last review to provide context for when information was current.
If you believe a page contains a factual error, please contact us with:
We review all correction submissions and respond within 5 business days. If the error is confirmed, we update the page and note when the correction was made.
Guidance pages are reviewed automatically on the first of each month. This process fetches current CDC and WHO guidance, compares it against page content, and applies corrections where authority sources directly contradict a specific claim. The "Last reviewed" date on each page reflects the most recent review, whether automated or manual.
8 entries are logged for CoronavirusQuestions.com, plus 3 applied across the whole network — each traceable to the change that made it. The least flattering entries are the point of publishing this.
What was published: The reference on the anti-vaccine movement page gave the DOI 10.1126/science.abf1568, which does not exist.
What it says now: The reference gives the paper's registered DOI, 10.1126/science.abj2258.
Source: doi.org and Crossref records, checked October 30, 2026
What was published: Novavax was described as "FDA authorized", Pfizer-BioNTech as having "full approval (adults and children)", and Moderna as releasing "bivalent and monovalent" formulations.
What it says now: FDA licensed Nuvaxovid on May 16, 2025, and FDA now lists Sanofi Vaccines US as its manufacturer. All four U.S. COVID-19 vaccines are approved for adults 65 and older and, under 65, only for people with a high-risk condition, from a youngest age that differs by product: 6 months (Spikevax), 5 years (Comirnaty), 12 years (mNEXSPIKE, Nuvaxovid). All are now single-strain (XFG) for 2026–2027.
Change: PR #354
What was published: The sites said every clinical page was reviewed monthly against live CDC and WHO guidance, and that "Last reviewed" dates reflected that review. In practice the automated review covered about half the guidance pages, saw only the first 9,000 characters of each, and advanced the date even when its sources failed to load, which by October 2026 most of its hard-coded CDC links did. One site also called its review history "public and auditable"; the repository is private. Several pages cited CDC and FDA URLs that now return "not found".
What it says now: The review was rebuilt to check whole pages against the sources each page cites, and to leave a page’s date unchanged if any part of its check fails. The pages now describe what is covered ("guidance pages") and what is not (cost analyses, history pages, the risk-data pages and study question banks). The dead citations were replaced with the current CDC, FDA and journal pages that state the cited facts.
Source: Network review audit, October 2026
What was published: The privacy policies said the sites display Google AdSense advertising and contain Amazon affiliate links, and described the related cookies and opt-outs. Neither has run on any site since July 2026. The CoronavirusQuestions.com policy also named Netlify as its host and form processor. No policy said what the cookie banner’s Decline button does, and Decline did not in fact turn analytics off.
What it says now: Each policy now says there is no advertising and there are no affiliate links, that none are planned for the foreseeable future, and that the policy will change before either appears. Hosting and form processing are named correctly (Cloudflare Pages, Formspree). Decline now turns Google Analytics off, and each policy has a control to see and change that choice.
Source: Site state verified 2026-10-04: monetization flag off on all five sites; contact forms post to Formspree.
What was published: The antivirals comparison said adolescents aged 12–17 are covered for Paxlovid under an Emergency Use Authorization, and that molnupiravir is available under an Emergency Use Authorization, both stated as current fact.
What it says now: FDA’s emergency-use page (checked 2026-10-04) no longer lists either drug, and the current Paxlovid label covers adults only. Because the authorization status could not be confirmed, the page now says both may be available under an emergency use authorization, though guidance here is fluid, and points readers to FDA’s current list. Full FDA approval of Paxlovid for adults and of remdesivir is unchanged.
Source: FDA — Emergency Use Authorization page; PAXLOVID label (DailyMed, revised February 2026)
What was published: The symptoms-by-variant table gave the original-strain column as 83% fever, 68% cough and 38% fatigue with no source named, and listed loss of smell or taste as a "hallmark symptom (30–60%)" of the original strain.
What it says now: The figures closest to those in the literature are the WHO-China Joint Mission report of February 2020, based on 55,924 laboratory-confirmed cases: fever 87.9%, dry cough 67.7%, fatigue 38.1%. That report does not record loss of smell or taste at all — the symptom was not yet recognised when it was compiled. Every quantified cell in the table now names its study, and the Delta/Omicron columns carry the matched-cohort figures from Menni et al. (The Lancet, 2022) with their odds ratios and confidence intervals.
Source: WHO-China Joint Mission report (February 2020); Menni C, et al., The Lancet 2022, doi:10.1016/S0140-6736(22)00327-0
What was published: The Long COVID page presented a twelve-item list as "the 12 symptoms most predictive of Long COVID" identified by the NIH RECOVER Initiative. Five items on it — shortness of breath, headache, sleep disturbances, joint or muscle pain, and anxiety or depression — are not in the published PASC score, and five that are — gastrointestinal symptoms, changes in sexual desire or capacity, thirst, chest pain, and abnormal movements — were missing.
What it says now: The page lists the twelve symptoms exactly as Thaweethai et al. published them, states that the score was built from 37 symptoms with adjusted odds ratios of 1.5 or greater across 9,764 participants, and shows the wrongly included symptoms separately with the explanation that they are common in uninfected people too and so carry little discriminating signal.
Source: Thaweethai T, et al. "Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection." JAMA 2023, doi:10.1001/jama.2023.8823
What was published: The How We Research page stated that the site "generates revenue through two disclosed mechanisms" and described Google AdSense advertising and Amazon affiliate links as live.
What it says now: Both were switched off network-wide and the About page had already been updated to say so; this page had not. It now states that the site earns nothing as of September 2026, that no advertising and no affiliate link appears on any indexable page, and that the disclosure will be updated on the day either changes.
Source: Site state verified in this review — the monetization flag is off and no ad or affiliate markup renders on any built page.
What was published: Lagevrio (molnupiravir) was listed as FDA "Approved."
What it says now: Available under Emergency Use Authorization only — not FDA-approved. Paxlovid’s full approval was also scoped to adults, with ages 12–17 remaining under EUA.
Change: PR #167
What was published: A dead Bureau of Economic Analysis URL for the 2020 GDP release, cited to the wrong month.
What it says now: Live URL restored and the release month corrected to January 2021.
Change: PR #167
What was published: Stored news items reproduced verbatim summary text from New York Times and BBC articles.
What it says now: All 42 stored summaries were removed retroactively across the news and archive sections of every spoke, and a headline-only policy adopted for those publishers going forward.
Change: PR #122
Entries begin in July 2026, when the network moved to a single repository and changes became individually traceable. Earlier corrections were not logged in a citable form and are not reconstructed from memory. The full network-wide log, including corrections on the other sites, is on VirusQuestions.com.